Hepatitis C virus and blood transfusion: Past and present risks

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 101-106

  Van Der Poel, Cees L ^a,b  

^a Division Research   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Anti HCV screening; Blood donation; Blood transfusion; HCV transmission

Indexed keywords

BLOOD ANALYSIS; BLOOD DONOR; BLOOD TRANSFUSION; CONFERENCE PAPER; DISEASE TRANSMISSION; HEPATITIS C; HUMAN; INFECTION RISK; PRIORITY JOURNAL; SCREENING TEST; VIRUS DETECTION;

EID: 0033458950     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80384-5     Document Type: Conference Paper

References (70)

1. Reesink HW, Van der Poel CL. Blood transfusion and hepatitis: still a threat? Blut 1989: 58: 1-6.
2. Zuck TF, Sherwood WC, Bove JR. A review of recent events related to surrogate testing of blood to prevent non-A, non-B posttransfusion hepatitis. Transfusion 1987: 27: 203-206.
3. Brind AM, Codd AA, Cohen BJ et al. Low prevalence of antibody to hepatitis C virus in North East England. J Med Virol 1990: 32: 243-248.
4. Van der Poel CL, Cuypers MTH, Reesink HW et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991: 337: 317-319.
5. Eastlund 1998.
6. Vrielink H, Van der Poel CL, Reesink HW et al. Look-back study of infectivity of anti-HCV ELISA positive blood components. Lancet 1995: 345: 95-96.
7. Donahue JG, Munoz A, Ness PM et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992: 327: 369-373.
8. Allander T, Medin C, Jacobson SH et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994: 43; 415-419.
9. Sampietro M, Baddalamenti S, Salvadori S et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int 1995:47:911-917.
10. DeLamballerie X, Olmer M, Bouchouareb D et al. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996: 49: 296-302.
11. Stuyver L, Claeys H, Wyseur A et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int 1996: 49: 889-895.
12. Dodd RY: Hepatitis C virus, antibodies and infectivity: paradox, pragmatism and policy. Am J Clin Pathol 1992: 97: 4-6.
13. Jarvis LM, Ludlam CA, Eilender JA et al. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood 1996: 87: 3007-3011.
14. Telfer P, Sabin C, Devereux H et al. The progression of HCVassociated liver disease in a cohort of haemophilic patients. Br J Haematol 1994: 87: 555-561.
15. Tagariello G, Pontisso P, Davoli PG et al. Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs. Br J Haematol 1995: 91: 708-713.
16. Makris M, Preston FE, Rosendaal FR et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996: 94: 746-752.
17. Mauser-Bunschoten EP, Bresters D, van Drimmelen AAJ et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995: 45: 241-246.
18. Mannucci PM, Zanetti AR, Colombo M et al. Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. Thromb Haemost 1990: 64: 232-234.
19. Schulman S, Lindgren AC, Petrini P et al. Transmission of hepatitis C with pasteurised factor VIII. Lancet 1992: 340: 305-306.
20. Mosley JW. Transmission of hepatitis C by pasteurised factor VIII. Lancet 1992: 340: 1160-1161.
21. Kreutz W, Auerswald G, Bröckmann C et al. Prevention of hepatitis C virus infection in children with hemophilia A and B and von Willebrands disease. Thromb Haemost 1992: 67: 184.
22. Manucci PM, Schimpf K, Abe LM et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Transfusion 1992: 32: 134-138.
23. Noel L, Guerois C, Maissoneuve P et al. Antibodies to hepatitis C virus in haemophilia. Lancet 1989: ii: 560.
24. Skidmore SJ, Pasi KJ, Mawson SJ et al. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. J Med Virol 1990: 30: 50-52.
25. Manucci PM, Schimpf K, Brettler DB et al. Low risk for hepatitis C in haemophiliacs given a high-purity, pasteurized factor VIII concentrate. Ann Int Med 1990: 113: 27-32.
26. Williams PE, Yap PL, Gillon J et al. Non-A, non-B hepatitis transmission by intravenous immunoglobulin. Lancet 1988: ii: 501.
27. Meisel H, Reip A, Faltus B et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995: 345: 1209-1211.
28. Power JP, Lawlor E, Davidson F et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995: 345: 1211-1213.
29. Healey CJ et al. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus - screened intravenous immunoglobulin therapy. Gastroenterology 1996: 110: 1307-1310.
30. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996: 104 SI: 3512.
31. CPMP Commission on Proprietary and Medicinal Products. The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools. CPMP/ BWP/390/97.
32. Dawson GJ, Lesniewski RR, Stewart JL et al. Detection of antibody to hepatitis C virus in U.S. blood donors. J Clin Microbiol 1991: 29: 551-556.
33. Van der Poel CL, Cuypers HTM, Reesink HW et al. Risk factors in HCV infected blood donors. Transfusion 1991: 31: 777-779.
34. Maclennan S, Barbara JA, Hewitt P et al. Screening blood donations for HCV Lancet 1992: 339: 131-132.
35. Moore SB, Kruger JR, Rakela J et al. Blood donors who are repeatedly reactive for hepatitis C virus on enzyme immunoassay and positive on recombinant immunoblot assay: evidence of failure to identify some risk factors. Transfusion 1995: 35: 308-312.
36. Kolho EK, Krusius T. Risk factors for hepatitis C virus antibody positivity in blood donors in a low risk country. Vox Sang 1992: 63: 192-197.
37. Kaldor JM, Arhcer GT, Buring ML et al. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med J Aust 1992: 157: 227-230.
38. Neal KR, Jones DA, Killey D et al. Risk factors for hepatitis C virus infection: a case-control study of blood donors in the Trent region (UK). Epidemiol Infect 1994: 112: 595-601.
39. Alter HJ, Purcell RH, Holland PV et al. Donor transaminase and recipient hepatitis. JAMA 1981: 246: 630-634.
40. Aach RD, Szmuness V, Mosley JW et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. N Engl J Med 1981: 304: 989-993.
41. Stevens CE, Aach RD, Hollinger FB et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. Ann Int Med 1984: 101: 733-738.
42. Koziol DE, Holland PV, Ailing DW et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 1986: 104: 488495.
43. Reesink HW, Leentvaar-Kuypers A, Van der Poel CL et al. NonA, non-B posttransfusion hepatitis in open heart surgery patients in The Netherlands: Preliminary results of a prospective study. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R. Liss; 1988. p. 558-560.
44. Widell A, Sundström G, Hansson BG et al. Relation between donor transaminase and recipient hepatitis non-A, non-B in Sweden. Vox Sang 1988: 54: 154-159.
45. Aymard JF, Janot C, Gayet S et al. Posttransfusion non-A, nonB hepatitis after cardiac surgery. Vox Sang 1986: 51: 236-238.
46. Esteban JI, Gonzales A, Hernandez JM et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 1990: 323: 1107-1112.
47. Blajchman MA, Bull SB, Feinman SV. Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian PostTransfusion Hepatitis Prevention Study Group. Lancet 1995: 345: 21-25.
48. Widell A. Antibody to hepatitis C virus related proteins in sera from alanine aminotransferase screened blood donors and prospectively studied recipients. Vox Sang 1991: 60: 28-33.
49. Van der Poel CL, Reesink HW, Schaasberg W et al. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 1990: 335: 558-560.
50. Van der Poel CL, Bresters D, Reesink HW et al. Early anti-hepatitis C virus response with second-generation C200/C22 ELISA. Vox Sang 1992: 62: 208-212.
51. Ebeling F, Naukkarinen R, Leikola J. Post-transfusion hepatitis C in Finland. Transfusion Med 1991: 1: 109-113.
52. Ebeling F. Second generation RIBA to confirm diagnosis of HCV infection. Lancet 1991: 337: 912-913.
53. Barrera JM, Bruguera M, Ercilla MG et al. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers. Ann Intern Med 1991: 115:596-600.
54. Van der Poel CL. ALT testing in prospective European trials. Proc Regional Conference of the International Society of Blood Transfusion (ISBT), Venice; 1995.
55. Busch MP, Korelitz JJ, Kleinman SH et al. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion. 1995: 35: 903-910.
56. Wolff C, Kleesiek K, Petersen N, Beyer J. Hepatitis C viremia in German blood donors: Serum alanine aminotransferase is not a valid marker for screening. Transfusion 1994: 34: 361-362.
57. Caspar! G, Gerlich WH, Beyer J, Schmitt H. Age, sex and transaminase dependency of specific and nonspecific results from enzyme immunoassays for antibodies to hepatitis C virus and follow-up of blood donors. Infusionsther Transfusionsmed 1995: 22: 208-219.
58. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989: 321: 1495-1500.
59. Miyamura T, Saito I, Katayama T et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: Application to diagnosis and blood screening for post-transfusion hepatitis. Proc Natl Acad Sei USA 1990: 87: 983987.
60. Kuo G, Choo Q-L, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989: 244: 362-364.
61. Tremolada F, Casarin C, Tagger A et al. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med 1991: 114: 277-281.
62. Barrera JM, Francis B, Ercilla G, et al: Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995: 68: 15-18.
63. Lee SR, Wood CL, Lane MJ, et al: Increased detection of hepatitis C virus infection in commercial plasma donors by a thirdgeneration screening assay. Transfusion 1995: 35: 845-849.
64. Vrielink H et al. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion 1997: 37: 845-849.
65. Slade BA, Grindon AJ. HCV 2.0: the next generation. Transfusion 1992: 32: S73 (Suppl).
66. Cyrus S, Swenson S, Dembowski J. Removal of HCV infected donors with use of second generation anti-HCV ELISA. Transfusion 1992: 32: S73 (Suppl).
67. Kleinman S et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfusion Med Rev 1997: 11: 155-172.
68. Damen M et al. Detection of hepatitis C virus RNA: application to diagnostics and research. In: Reesink H, editor. Current Studies in Hematology and Blood Transfusion, Vol 62. Basel: Karger; 1998. p. 67-101.
69. Schreiber GB, Busch M P, Kleinman SH et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996: 334: 1685-1690.
70. PEI Paul Ehrlich Institut. Bekanntmachung des Paul Ehrlich Instituts vom 25.2.1998 über die Ergebnisse des Stufenplanverfahrens des Risikos von Hepatitis B-, Hepatitis C-, und HIV Infectionen bei Empfängern von Erytrozytenkonzentraten, Baz. no. 63 vom 04.04.97, S4477.